They could be big winners for patient investors.
News & Analysis: Bristol-Myers Squibb
BMY earnings call for the period ending March 31, 2019.
The big drugmaker beat Wall Street estimates in the first quarter thanks to solid sales growth for its top blockbusters.
Drugmakers battle for patients.
These next-generation companies are working on game-changing ways to obtain and profit from genetic insight.
Why Celgene Shareholders Should Hold On to Their Bristol-Myers Squibb Stock Once the Acquisition Closes
The fat lady is getting ready to sing with this big pharma deal. Celgene shareholders will soon have a decision to make.
Elsewhere, the merger between Bristol-Myers Squibb and Celgene got some votes of confidence.
An activist investor made a strong argument for walking away from Celgene, but will investors listen?
Opposition to letting Bristol-Myers eat Celgene is continuing to mount ... among Bristol-Myers shareholders.
The drugmaker's fourth-quarter results were great. It's the prospects for future quarters that make the Celgene deal look appealing.